Brigham Young University

BYU ScholarsArchive
All Theses and Dissertations

2016-07-01

Cognitive Functioning in Multiple Sclerosis: An
Investigation of the Utility of a Computerized
Cognitive Testing System
Stephanie Patrice McLaughlin
Brigham Young University

Follow this and additional works at: https://scholarsarchive.byu.edu/etd
Part of the Psychology Commons
BYU ScholarsArchive Citation
McLaughlin, Stephanie Patrice, "Cognitive Functioning in Multiple Sclerosis: An Investigation of the Utility of a Computerized
Cognitive Testing System" (2016). All Theses and Dissertations. 6013.
https://scholarsarchive.byu.edu/etd/6013

This Dissertation is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in All Theses and Dissertations
by an authorized administrator of BYU ScholarsArchive. For more information, please contact scholarsarchive@byu.edu, ellen_amatangelo@byu.edu.

Cognitive Functioning in Multiple Sclerosis: An Investigation of the Utility of a
Computerized Cognitive Testing System

Stephanie Patrice Bown McLaughlin

A dissertation submitted to the faculty of
Brigham Young University
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy

Ramona O. Hopkins, Chair
Erin D. Bigler
Scott R. Braithwaite
Shawn D. Gale
Dawson W. Hedges

Department of Psychology
Brigham Young University
July 2016

Copyright © 2016 Stephanie Patrice Bown McLaughlin
All Rights Reserved

ABSTRACT
Cognitive Functioning in Multiple Sclerosis: An Investigation of the Utility of a
Computerized Cognitive Testing System
Stephanie Patrice Bown McLaughlin
Department of Psychology, BYU
Doctor of Philosophy
The primary objective of this study was to assess cognitive functioning in participants
with relapsing remitting multiple sclerosis (RRMS) using the MicroCog and to compare their
performance to that of a demographically matched, healthy control group. It was hypothesized
that as a group, participants with RRMS would have worse cognitive function than healthy
controls on all Level 1, 2, and 3 Index scores of the MicroCog. Twenty-six participants with
RRMS and twenty-nine sex and education matched healthy controls were administered the
MicroCog (Standard Form) along with measures of depression and clinical status, and paperpencil tests of processing speed (Symbol Digit Modalities Test; SDMT and Paced Auditory
Serial Addition Test; PASAT). A series of ANCOVAs with depression as a covariate was
performed to determine between group differences for each MicroCog Level 3 Index score
(General Cognitive Proficiency (GCP) and General Cognitive Functioning (GCF)), Level 2
Index score (Information Processing Accuracy (IPA) and Information Processing Speed (IPS)),
and Level 1 Index score (Attention/Mental Control, Memory, Reasoning/Calculation, Spatial
Processing, and Reaction Time). Pearson’s and point biserial r correlations were calculated in
order to assess the degree to which Level 2 and 3 Index scores correlated with clinical and
demographic factors (sex, disease duration, depression, and clinical status) and to correlate the
MicroCog IPS index score with traditional measures of processing speed. Eight RRMS and two
control participants met criteria for cognitive impairment on the MicroCog. ANCOVA results
indicated there were significant differences between RRMS and control performance for two
MicroCog scores (GCF and IPS). There were not significant differences for GCP, IPS, and all
Level 1 scores. A post-hoc analysis performed for the same hypothesis with a group of age
equivalent participants suggested a significant RRMS by depression interaction for Level 3
scores. RRMS was not predictive of Level 2 scores after controlling for depression in the age
equivalent sample. Correlations for clinical and demographic factors with cognitive outcomes
indicated significant relationships for clinical status and depression. There was not a significant
relationship detected for disease duration or sex. MicroCog and processing speed measures were
significantly related. Post-hoc analyses supported that the criterion validity of the MicroCog is
comparable to other cognitive screening tools in RRMS. The results and limitations of our study
are discussed, in addition to recommendations for future research.
Keywords: multiple sclerosis, cognitive impairment, computerized cognitive assessment
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1
Cognitive Functioning in Multiple Sclerosis: An Investigation of the Utility of a
Computerized Cognitive Testing System
Multiple Sclerosis (MS) is the most common non-traumatic neurological illness that
affects young and middle-aged adults (Joy & Johnston, 2001; Rao, 1990; Rejdak, Jackson, &
Giovannoni, 2010). The worldwide prevalence rate of MS is estimated to be approximately two
million, with 300,000 to 350,000 individuals with MS in the United States (Fox, Bethoux,
Goldman, & Cohen, 2006; Joy & Johnston, 2001; Kalb & Reitman, 2010; Noonan et al., 2010).
Due to the debilitating nature of MS and its onset early in adulthood, the costs associated with
MS and its treatment is high. A 1998 study estimated the national annual cost of MS in the
United States as 6.8 billion dollars, with a total lifetime cost of $2.2 million per individual with
MS (Whetten-Goldstein, Sloan, Goldstein, & Kulas, 1998). More recent estimates from the
National Multiple Sclerosis Society estimated that health-care costs average nearly $70,000 a
year per individual with MS (Krishnan, 2007).
Over the past several decades, research has described the cognitive deficits associated
with MS. It is estimated that 40 to 65% of individuals with MS experience some form of
cognitive impairment during the course of the disease (Rao, 1995; Amato, Zipoli, & Portaccio,
2006; Rao, Leo, Bernardin, & Unverzagt, 1991). Cognitive deficits can have detrimental impact
on an physical health, as well as social, occupational, and psychological functioning in
individuals with MS (Amato, Ponziani, Siracusa, & Sorbi, 2001; Glanz et al., 2010; Rao, 2004b;
Rao, 1991b; Shevil & Finlayson, 2006). The purpose of this investigation is to explore the utility
of the MicroCog, a computerized cognitive testing system in assessing cognitive function in MS
populations.
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Multiple Sclerosis
Multiple sclerosis is a chronic degenerative disorder of the central nervous system.
Multiple sclerosis is an inflammatory demyelinating disease, distinguished by widespread white
matter lesions throughout the brain and spinal cord that interrupt the conduction of nerve
impulses and lead to reversible and irreversible neurologic morbidity. Some forms of MS are
restricted to axonal dyemyelination, while others (particularly the more chronic, progressive
forms) are linked to axonal damage, axonal degeneration and neuronal death (Fox et al., 2006;
Goodin et al., 2002; Joy & Johnston, 2001; Rao, 1990). Lesions can occur in any white matter
region of the central nervous system and commonly occur in the optic nerves, periventricular
region, corpus callosum, brain stem white matter, cerebellum, and spinal cord (Lezak, Howieson,
Bigler, & Tranel, 2012). Symptoms of MS include coordination abnormalities, visual
difficulties, bladder dysfunction, bowel symptoms, sexual dysfunction, cognitive impairments,
and fatigue. Patients experience various levels of disability, with some individuals being able to
function normally for the majority of their illness while others progress rapidly towards severe
disability (Joy & Johnston, 2001).
The symptoms of MS are heterogeneous, making diagnosis difficult. There is no specific
laboratory test for MS and diagnosis is based on patient history, neurologic examination, and
other clinical tests, such as evoked potentials or MRI of the brain and spine (Fox et al., 2006; Joy
& Johnston, 2001; Rao, 1990). Onset of MS typically occurs between the ages of 15 to 50 years,
with the mean age of onset around 30 years (Rao, 1990). A particularly devastating aspect of MS
is its tendency to present with little or no warning (the first symptoms are typically quite mild) as
individuals are beginning to establish their family and careers. Life expectancy is reduced by
approximately 10-15 years with around half of patients living 30 years or more after disease
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diagnosis. Multiple sclerosis is more common in women (about two-thirds of those diagnosed),
in individuals from a North European heritage, and in individuals who live in high latitudes
during childhood (Joy & Johnston, 2001).
The clinical course of MS is variable and is characterized by relapses or flare-ups
(episodic acute periods of worsening or inflammation), gradual progressive deterioration of
neurologic function, or combinations of both. Four clinical courses or types of MS have been
described based on disease course, including: relapsing-remitting, secondary progressive,
primary–progressive and progressive-relapsing. Relapsing-remitting MS (RRMS) occurs in
about 85% of patents and is defined as “clearly defined disease relapses with full recovery or
with sequelae and residual deficits upon recovery” (Fox et al., 2006; Lublin & Reingold, 1996).
During relapses, acute symptoms will develop over several days, typically become most severe
after 1 to 2 weeks, and then gradually resolve. After 10-20 years into the RRMS course, the
disease typically progresses and develops into secondary progressive MS. In secondary
progressive MS, neurological symptoms gradually worsen and patients experience occasional
relapses, minor remissions, and plateaus. Many patients with RRMS transition into secondary
progressive MS later in the disease course. A third clinical course is primary-progressive MS
which is defined as “disease progression from onset with occasional plateaus and temporary
minor improvements allowed” (Lublin & Reingold, 1996). About 15% of patients present with
primary progressive MS, which is characterized by gradual worsening of neurological symptoms
(Fox et al., 2006). Finally, progressive-relapsing MS and is a “progressive disease, with clear
acute relapses, with or without full recovery with periods between relapses characterized by
continuing progression” (Lublin & Reingold, 1996). Progressive-relapsing MS occurs in about
5% of patients (Fox et al., 2006).

4
Currently there is no cure for MS, but there is increased optimism for new treatments as
research advances have begun to elucidate the underlying mechanisms of the disease. Treatment
is aimed at slowing the progression of pathology and emphasis is placed on early detection and
intervention to maximize treatment effects. Managing the disease can be quite complex
depending on the needs and symptoms of the individual patient, but typically involves the use of
disease modifying agents (immunomodulating medications), treatment of acute exacerbations
with corticosteroids, medications used to treat the various symptoms of MS (e.g. fatigue,
depression, etc.), physical and occupational rehabilitation, and psychosocial support (Fox et al.,
2006; Kalb & Reitman, 2010; Rao, 1990).
Cognitive Impairments in Multiple Sclerosis
Cognitive impairment as a common feature of multiple sclerosis (Prakash, Snook, Lewis,
Motl, & Kramer, 2008; Rao et al., 1991c) and can adversely affect the individual’s ability to
function normally in their daily life. Participants with MS who were cognitively intact were
compared to those with cognitive impairment, and individuals with cognitive impairment were
less likely to be employed, engaged in fewer leisure and social activities, were more likely to
have psychiatric disorders (e.g. depression, anxiety), and have greater difficulty performing
household tasks (Rao, 1991b). Cognitive impairment has significant negative impact on driving
performance even in MS participants with minimal to no physical impairment (Schultheis,
Garay, Millis, & DeLuca, 2002). Cognitive impairment can occur regardless of MS type and can
occur in early stages of the disease, even before full criteria for MS is met (Achiron & Barak,
2003; Camp et al., 1999; De Sonneville et al., 2001; Deloire et al., 2011; Deloire et al., 2005;
Foley, Benedict, Gromisch, & DeLuca, 2012; Glantz et al., 2010; Huijbregts, Kalkers, de
Sonneville, de Groot, & Polman, 2006; Rao, 1991c)). There is evidence for unique cognitive
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deficit profiles depending on MS course type. Patients with progressive forms of MS have
significantly worse cognitive function than patients with RRMS for memory, working memory,
and attention (Huijbregts et al., 2006).
Specific cognitive deficits can vary between patients in regards to type and severity
(Lezak et al., 2012). A number of cognitive domains have been found to be impaired in crosssectional and longitudinal studies, including attention, memory, processing speed, executive
function, and language.
Cognitive impairments may vary over time depending on disease course. For example, a
longitudinal study investigated the progression of cognitive impairment (at intervals of four and
ten years) in 50 MS participants compared to 70 healthy controls matched for sex, age, and
education level (Amato et al., 2001). The number of participants who had cognitive
impairments (i.e., MS participants whose scores fell below the fifth percentile of the study’s
control group) increased over time. Thirteen out of 50 MS participants had impairments on three
or more subtests at year one and 25 participants had impairments three or more subtests at year
ten. Across the study period the cognitive deficits were most common for verbal memory and
abstract reasoning. Compared to four years, after ten years the type of deficits expanded to
include impairments in linguistic functioning, attention, and short term memory (Amato et al.,
2001). A second longitudinal study compared 22 RRMS participants’ neuropsychological
performance at year one to their performance approximately 18-years later (Strober, Rao, JarChi, Fischer, & Rudick, 2014). Nine participants (41%) were cognitively impaired (i.e., had two
or more test scores that fell 1.5 standard deviations or more below the normative mean) at study
entry. The number of participants with cognitive impairment increased to 13 (59%) at 18-year
follow-up, an approximately 44% increase. At study entry, information processing speed, word
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list learning, and memory were impaired and continued to deteriorate over time. Attention,
working memory, and visuospatial abilities also were impaired at 18-year follow up.
Neuroradiological and pathological studies help elucidate some of the anatomical
correlates and patterns in cognitive impairment in MS. A review of MRI studies by DeLuca,
Yates, Beale, and Morrow (2015) found a relationship between cognitive impairment and T2

white matter lesion volume. No significant relationship between white matter lesion distribution
and cognitive impairment has been consistently identified. The exception is the corpus callosum,
where MS participants with a higher lesion volume in the corpus callosum are more likely to be
cognitively impaired. Both white matter and gray matter damage have been implicated in MS
pathogenesis, and damage to the hippocampus, thalamus, nucleus accumbens, and basal ganglia
are thought to play a role in cognitive impairment. Deluca et al. postulated that, based on results
of post-mortem studies, damage along white matter tracts that connect areas of cortical and deep
gray matter structures may be the best way to illustrate cognitive impairment in MS (i.e., white
matter and gray matter forming circuits that are involved in a specific type of cognitive
functioning, such as memory formation). Detailed information regarding specific domains of
cognitive impairments is below.
Memory. A 2008 meta-analysis found memory impairments were the most frequent
cognitive impairment in MS participants (Prakash et al., 2008). Immediate verbal memory is the
most extensively studied domain of impairment with an effect size of g=-0.59 (p<.05) based on
75 studies. The second most studied domain is verbal delayed recall memory with an effect size
g=-0.77 (p<.05) based on 44 studies. Visual immediate and delayed recall and verbal recognition
memory deficits were also prominent. There are efforts to delineate whether deficits in memory
are more likely due to poor initial learning as opposed to retrieval deficits, and there is evidence
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emerging for the former argument (DeLuca, Leavitt, Chiaravalloti, & Wylie, 2013; Lafosse,
Mitchell, Corboy, & Filley, 2013). Brissart, Morele, Baumann, & Debouverie (2012) used
scores of verbal episodic memory tests for 426 participants with MS and found a high prevalence
of memory impairment in MS. A pattern emerged where deficits in information retrieval were
more common in the early stages of MS and then there was an increase in memory deficits as the
disease progresses.
Several studies have found MS participants perform significantly worse than healthy
controls for working memory. A meta-analysis found working memory impairment (effect size
g=0.51, p<.05) based on 85 studies (Prakash et al., 2008). Participants with MS performed
worse on more challenging working memory tests (e.g. PASAT, Digit Span Backward) rather
than simple tests of working memory (e.g. Digit Span Forward). The PASAT is one of the most
specific (Rao et al., 1991c) and widely used measures of working memory used in MS
populations (Fischer, Rudick, Cutter, & Reingold, 1999). One study of 215 participants with MS
found slow processing speed was more common than deficits in working memory (DeLuca,
Chelune, Tulsky, Lengenfelder, & Chiaravalloti, 2004).
Attention. Like other domains, the severity of impairment in attention is heterogeneous
across studies (McCarthy, Beaumont, Thompson, & Peacock, 2005; Paul, Beatty, Schneider,
Blanco, & Hames, 1998). Studies also vary in their definition of types of attention studied (e.g.
controlled, simple, focused, divided, etc.). It appears that MS participants have impairments in
divided attention and alternating attention (Chiaravalloti & DeLuca, 2008; Lezak et al., 2012;
Rao et al., 1991c) whereas simple attention is more likely to remain intact. Prakash et al. (2008)
found impaired sustained and selective focused attention in MS participants.
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Processing speed. Many individuals with MS report feeling mentally slow and have
difficulty thinking quickly or keeping up with the pace of normal conversation (Lezak et al.,
2012). Information processing and response time deficits are consistently reported deficits in
MS populations (Covey, Zivadinov, Shucard, & Shucard, 2011; Jennekens-Schinkel, Sanders,
Lanser, & Van der Velde, 1988; McCarthy et al., 2005; Paul et al., 1998). Studies have found
information processing speed is slower early in the disease course, while working memory
deficits increase as the disease progresses to SPMS (Archibald & Fisk, 2000; DeLuca et al.,
2004). Some authors have argued that processing speed deficits might account for performance
deficits in other cognitive domains (e.g., executive functioning) (Chiaravalloti, Stojanovic-Radic,
& DeLuca, 2013; Owens, Denney, & Lynch, 2013).
Executive function. Executive functioning deficits are commonly identified in
participants in MS (Chiaravalloti & DeLuca, 2008; Lezak et al., 2012; Rao, 2004a), but, like
other cognitive domains, there is inconsistency in assessment tools and operational definitions of
executive dysfunction making across study comparisons difficult (Denney, Hughes, Owens, &
Lynch, 2012). Drew, Tippett, Starkey, & Isler (2008) assessed executive function in 95 MS
participants using the Delis-Kaplan Executive Function System (DKEFS). The majority of MS
participants (63%) scored more than one standard deviation below the mean on at least one
measure. Sixteen of the participants had widespread difficulties in executive function however,
there was little consistency in which type executive function (e.g. reasoning, decision making,
inhibition of responses) was impaired. Impairments also occur on timed tasks of executive
function (e.g., Stroop Test) suggesting that response time might, at least in part, may contribute
to the observed impairments in executive function (Macniven et al., 2008). Prakash et al., also
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found impaired executive functioning in MS participants (effect size g=0.51, p<.05) based on 29
studies (2008).
Language. Lezak et al. (2012) noted that language abilities typically remain unaffected
in MS participants except when rapid and efficient retrieval is needed, such as in verbal fluency
tasks. Tests of verbal fluency, comprehension, verbal expression, and verbal discourse (g=0.28, p<.05) are often impaired (Prakash et. al, 2008). Other studies find impairments in naming
and verbal and category fluency (Friend et al., 1999).
Visuospatial. Few studies assess visuospatial impairments in MS. Prakash et al. (2008)
found MS groups were more impaired for visuoconstruction compared to controls. Similarly,
Rao et al. (1991c) found that MS participants performed significantly worse than controls on
tests of visual-spatial function (i.e., Benton Judgment of Line Orientation and Facial
Recognition).
Clinical Correlates of Cognitive Status in Multiple Sclerosis
Efforts to develop methods to predict, measure, and track change over time in cognitive
impairments in MS have focused on the relationships between cognitive deficits with
demographic or disease characteristics. There are inconsistencies in literature concerning the
association between cognitive impairment and clinical or demographic variables, including
longer disease duration, older age, physical disability, fatigue, sex, and education (Achiron &
Barak, 2003; Achiron et al., 2005; Amato et al., 2001; Bagert, Camplair, & Bourdette, 2002;
Brassington & Marsh, 1998; Chiaravalloti & DeLuca, 2008; Glanz et al., 2007; Johnson,
Gudrun, DeLuca, Leo, & Benjamin, 1997; Krupp & Elkins, 2000; Lynch, Parmenter, & Denney,
2005; Prakash et al., 2008; Rao et al., 1991c; Reuter et al., 2010; Thornton & Raz, 1997;
Zakzanis, 2000). To illustrate, review of four large studies of correlates of cognitive impairment
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in MS (Rao et al., 1991c, Amato et al., 2001, Prakash et al., 2008; Borghl et al., 2013) indicated
mixed results when assessing the relationship between demographic (e.g. age, female sex) and
clinical variables (e.g. longer disease duration, physical disability) with cognitive impairments.
Rao et al., found that physical disability (weakly) predicted cognitive impairment, whereas
longer disease duration and MS course did not predict cognitive impairment. Amato et al. found
that older age, physical disability, and a progressive disease course correlated with severity of
cognitive decline over time. Prakash et al., found that participants over 40 years old were more
likely to have cognitive impairments compared to younger individuals and studies that included
only females found higher rates of cognitive impairment compared to studies that enrolled both
males and females. Further there was no effect for physical disability or disease course, however
these effects may be domain specific such that clinical factors only predict performance on some
measures such as learning and memory. Borghl et al. (2013) identified factors associated with
cognitive impairment in a large sample of participants with RRMS (n=267) compared to healthy
controls (n=279). Results indicated that female sex, lower education, anxiety, and lower
intelligence were not predictive of cognitive impairment. When controlling for covariance
between these factors, the final model found longer duration of illness, physical disability, and a
lower vocabulary scale predicted cognitive impairment.
A covariate not discussed above that has received increased attention in research focused
on cognition in MS is depression. Depression is common in patients with MS (Lezak et al.,
2012) and is associated with impaired working memory, processing speed, memory, abstract
reasoning, and executive functioning (Chiaravalloti & DeLuca, 2008). A recent review of the
effects of depression (Feinstein, Magalhaes, Richard, Audet, & Moore, 2014) found a higher
prevalence of depression in MS relative to the general population. Participants with severe
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depression were found to have greater difficulties with working memory, executive functioning,
and information processing speed than participants with fewer depression symptoms. Also,
structural brain changes in MS have been associated with depression symptoms (in addition to
genetic, immunological, and psychosocial factors of MS). For example, atrophy in areas like
the dominant anterior temporal areas and dominant medial inferior frontal regions have been
associated with worse depression in MS. Feinstein et al. describe that diffusion tensor imaging
studies found lower fractional anisotropy in normal appearing white matter and higher mean
diffusivity in normal appearing gray matter in these same areas for participants with more severe
depression. Other studies found abnormalities in pathways (i.e., ventrolateral prefrontal cortex
and the amygdala) involved in mood regulation in MS participants with depression.
Summary of Cognitive Impairments
Participants with MS are more likely than healthy controls to have cognitive deficits in
multiple cognitive domains (i.e. memory, attention, processing speed, executive functioning,
visuospatial, and language). Participants with MS tend to perform worse than healthy controls
for verbal recall and verbal immediate memory, as well as working memory and complex
attention. Slow processing speed is also common and may affect performance on tests of
executive function. The domains and severity of the cognitive impairment in MS are
heterogeneous and vary widely between and within individual patients. Cognitive impairment
can occur at any time during the course of MS, including in the very early stage of the disease.
There are no consistent clinical and demographic factors found to be associated with cognitive
function in MS but there is empirical support for female sex, age, education, physical disability,
disease duration, course type, and depression as possible correlates.
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Neuropsychology Assessment
Research has supported the importance of early recognition and subsequent monitoring of
cognitive deficits in MS. Identification of cognitive deficits may allow for disease modifying
medications to be introduced sooner so disease progression can be delayed and cognitive
functioning preserved (Achiron & Barak, 2003; Bagert et al., 2002; Lensch et al., 2006; Patti et
al., 2009). Certain disease modifying medications, such as interferon β-1a, may prevent physical
and cognitive deterioration in individuals with RRMS (Fischer et al., 2000). Recent
investigations have assessed the use of acetylcholinesterase inhibitors to target the prevention of
cognitive decline in MS (Christodoulou, MacAllister, McLinskey, & Krupp, 2008; Krupp et al.,
2011). Awareness of cognitive deficits might also aid in decision making surrounding
psychosocial issues, such as driving, employment, and levels of independence, and approaches
towards rehabilitation (Chiaravalloti & DeLuca, 2008; Lezak et al., 2012; Rao, 1991b; Schultheis
et al., 2002).
Neuropsychological instruments are considered the gold standard for measuring a
patient’s cognitive functioning and change in cognition over time (Achiron & Barak, 2003;
Calabrese, 2006; Joy & Johnston, 2001; Lensch et al., 2006; Patti et al., 2009; Rao, 1995; Rudick
et al., 1996; Wallin, Wilken, & Kane, 2006). While a comprehensive neuropsychological
examination of patients with MS would be ideal (Lezak et al., 2012), it is often unrealistic to
refer each patient for a full battery of neuropsychological tests due to patient fatigue and
financial costs. Therefore, there is a need for a brief, reliable cognitive instrument that could be
used in outpatient settings to screen for and identify MS patients at risk for cognitive impairment
(Foley et al., 2012; Lensch et al., 2006; Rao et al., 1991c). Cognitive impairments on such tests
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may also be used to identify individuals in which comprehensive neuropsychological testing is
warranted.
Current brief cognitive tests are available are predominantly in paper-pencil form and
include the Brief Repeatable Battery of Neuropsychological Tests (BRB-N), the Mini Mental
Status Exam (MMSE), and the Paced Auditory Serial Addition Test (PASAT). The BRB-N has
good specificity in detecting cognitive impairments in MS participants (Scherer, 2007) and is a
cost effective, widely used measure (Boringa, et al., 2001), but does not include normative data
(Rao, 1991a). The PASAT is included as part of a widely used clinical outcome measure in MS,
the Multiple Sclerosis Functional Composite (MSFC) task (Fischer, Jak, Kniker, Rudick, &
Cutter, 2001). The PASAT has good specificity but has been criticized for its moderate
sensitivity (Rogers & Panegyres, 2007; Scherer, 2007). The PASAT measures only processing
speed and attention, and can result in significant frustration for individuals who take the test due
to test difficulty (Tombaugh, 2006). Given that deficits in mental processing speed are common
in MS, a measure of mental processing speed that does not frustrate patients is needed. Although
convenient and cost efficient, the MMSE has low sensitivity in detecting cognitive impairment in
MS (28-36%) and is not generally recommended as a screening tool in this population (Rao et
al., 1991c; Rogers & Panegyres, 2007; Scherer, 2007).

Although these instruments are useful

to clinicians, there continues to be a need for a time and cost efficient tests that tap a wide variety
of cognitive domains, has good psychometric properties, is easy to administer, and can be used to
identify or screen for cognitive impairments in an outpatient setting (Foley et al., 2012).
Computerized cognitive assessment. The use of a computerized cognitive test is a
seemingly ideal way to improve screening for cognitive impairment in MS. There are several
advantages to computerized neuropsychological assessment compared to paper and pencil tests.

14
Computerized assessments allow for more accurate measurement of time-sensitive tasks.
Administrators have the ability to integrate and automate interpretive algorithms (e.g.
statistically reliable change) (Bauer, et al., 2012). Administration is standardized, and therefore
administration error is reduced (Elwood, 2001). Other advantages include the ability to
administer multiple tests simultaneously, speed of scoring, ease of data handling and analysis,
and more precise quantification of reaction times (Powell et al., 2004). Few computerized
cognitive batteries have been investigated in participants with MS (Lapshin, O'Connor, Lanctôt,
& Feinstein, 2012).
MicroCog
The MicroCog is a computerized testing system that assesses neurocognitive functioning
in adults. There are 18 subtests which are combined into summary scores for nine interrelated
cognitive areas including Level 1 (Attention, Memory, Spatial Processing,
Reasoning/Calculation, Reaction Time), Level 2 (Information Processing Accuracy, Information
Processing Speed), and Level 3 (General Cognitive Functioning and General Cognitive
Proficiency). Due to its ease of administration and evidence for its capability to detect a wide
range of cognitive deficits in other clinical populations, it is a good candidate for use as a
screening tool for cognitive impairment in MS (Powell et al., 2004). The MicroCog is one of the
first commercially marketed computerized test batteries (Elwood, 2001) and used as a clinical
tool and outcome measure with a variety of populations, including: adult participants with
epilepsy, military veterans, cardiac surgery participants, physicians referred for competency
evaluations, National Football League players, and United States Air Force pilots (Holliday &
Costello, 1997; Korinek, Thompson, McRae, & Korinek, 2009; Willeumier, Taylor, & Amen,
2012).

In a 2008 review of computerized cognitive batteries for detecting cognitive changes in
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older adults, compared to other computerized cognitive tests the MicroCog had equal to or better
normative data, comprehensiveness of cognitive domains covered/depth of coverage within
domains, reliability, and validity (Wild, Howieson, Webbe, Seelye, & Kaye, 2008). The
MicroCog is a particularly well suited computerized assessment battery to be used in patients
with MS. A particular strength of the MicroCog is the test’s focus on and precise measurement
of processing speed, a common symptom in many forms of neuropathological disease processes
including MS (Lezak et al., 2012). This focus gives incremental utility to the MicroCog over
paper-and-pencil neuropsychological tests and other computerized assessment batteries where
accuracy is the sole focus, and allows more detailed interpretations of performance deficits. For
example, interpretation guidelines for the MicroCog indicate that the Alphabet subtest, a test that
follows a continuous-performance paradigm, helps the examiner to determine whether impaired
performance is indicative of impaired information processing speed as opposed to impulsivity.
Global scores of processing speed and accuracy allow evaluators to determine a patient’s overall,
across subtest, performance pattern (e.g. slow and accurate versus fast and inaccurate) and
whether the differences between the scores are statistically significantly relative to the normative
population. Given these features of the MicroCog, it is a promising candidate for use with
patients with MS.
The MicroCog is used as a screening test or a diagnostic tool as part of a general
neurological examination. There are two forms of the MicroCog available, a long form which
takes about one hour to administer and consists of 18 subtests, and a short form which takes
about 30 minutes to administer and contains 12 subtests. The MicroCog can be administered on
almost any laptop or desk top computer (PsychCorp, 2012). The test is designed to assess
normal and neurologically impaired or elderly individuals as it allows for breaks during test
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administration and uses minimal keys on the computer (limited to the numeric keypad (0-9),
“Backspace” and “Enter” keys, and the letter “P”) (Powell et al., 2004).
MicroCog scoring and interpretation. Figure 1 gives a description of the scores and
interpretation derived from the MicroCog. At the most basic level are the individual subtest
scores. The individual scores provided by each subtest are variable, and yield age and education
adjusted scores. These individual subtest scores are computed and are converted to scaled scores
(M=10, SD±3) with higher scores corresponding with better performance. Percentile ranks,
qualitative descriptions (i.e. Below Average-Above Average), and 95% confidence intervals are
also provided. Along with scores from individual subtest scores are three higher levels of score
interpretation. Level 1 includes scores for five cognitive domains including: Attention/Mental
Control, Memory, Reasoning/Calculation, Spatial Processing, and Reaction Time. Table 1
displays the various subtests within each of these cognitive domains.
Level 2 provides scores for overall information processing speed (IPS) and information
processing accuracy (IPA). Level 3 provides Global Cognitive Function (GCF) and Global
Cognitive Proficiency (GCP) scores. For Levels 1-3, the sums of corresponding subtest standards
scores are converted to a scale with a mean of 100 and standard deviation of 15, with higher
scores indicative of better performance.
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Cognitive Functioning
Level 3

Cognitive Proficiency
Global score based on interaction between

Global score based on Information Processing

accuracy and speed of performance with primary

Speed and Accuracy Scores

emphasis on accuracy

Level 2

Information Processing Speed

Information Processing Accuracy

Global score of average response time, accuracy

Global score of performance accuracy, response

disregarded

time disregarded

Attention/
Mental Control
Level 1

Memory
Subtests

Reaction

Spatial

Reasoning/

Time

Processing

Calculation

Subtests

Story 1

Subtests

Subtests

Subtests

Numbers Forward

Story 2

Timers 1

Clocks

Analogies

Numbers Backward

Address

Timers 2

Tic Tac 1, 2

Math

Alphabet

Object Match A

Figure 1. Levels of MicroCog index scores.
MicroCog psychometrics. The MicroCog was normed on a sample of adults aged 18-89
years that was representative of the US population (based on the 1988 census) in terms of age,
race, and education. The sample contained 810 adults, 90 for each age grouping. The MicroCog
has virtually no ceiling effects and thus can be used to test a wide range of individuals, including
highly educated individuals (Elwood, 2001). The MicroCog subtests (Table 1) compare
favorably with comprehensive neuropsychological test batteries (Elwood, 2001).
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Table 1
MicroCog Level 1 Index scores and descriptions
MicroCog
Index

Subtests

Attention/

Numbers Forward

Based off Digit Span Forward paradigm, simple attention

Mental

Numbers Reversed

Based off Digit Span Backward paradigm, mental

Control

Description of task

control/working memory
Alphabet

Adapted from continuous performance paradigm, sustained
focused attention with letters

Wordlist 1

Adapted from continuous performance paradigm, sustained
focused attention with words

Memory

Wordlist 2

Incidental learning of words from Wordlist 1

Story 1 and 2

Verbal memory, immediate and delayed recall

Address
Reasoning/

Analogies

Modeled after Millers Analogies Test; inductive reasoning

Calculation

Object Match

Modeled after Visual Verbal Test; Concept formation and
cognitive flexibility

Math Calculations

Mental calculations; Basic arithmetic operations; modeled
from WAIS-III Arithmetic subtest

Spatial
Processing
Reaction
Time

Tic Tac Subtest

Short term recall of location of stimuli on a gridlike matrix

Clocks

Visuoperceptual analysis of clock faces

Timers 1 and 2

Simple reaction time in auditory and visual modalities;
time elapsing between stimuli and response
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Reliability of the MicroCog. Table 2 provides a summary of the reliability of the
MicroCog by level of interpretation (subtests and Levels 1-3) for the normative age group of 18
to 44 years. There is limited research on the reliability and validity of the MicroCog in clinical
populations.
Table 2
MicroCog Reliability Summary
Reliability Coefficients

𝑎,1

Average reliability coefficient

𝑆𝑆𝑀

1

Decision Consistency Reliability𝑏,1
Average Stability Coefficient

Subtest (total score): 0.74

Average 𝑆𝑆𝑀

Subtest (total score): 1.47

Subtest (total score): 0.84

Level 1: 0.87

Level 1: 5.29

Level 1: 0.85

Level 2: 0.93

Level 2: 3.79

Level 2: 0.86

Level 3: 0.95

Level 3: 3.35

Level 3: 0.91

Reliability Coefficient Range:
Subtest (total score): 0.58-0.98

𝑆𝑆𝑀 Range:

Subtest (total score): 0.42-1.94

Stability Coefficient Range
Subtest (total score): 0.73-0.96

Level 1: 0.83-0.94

Level 1: 3.67-6.18

Level 1: 0.73-0.96

Level 2: 0.92-0.95

Level 2: 3.35-4.24

Level 2: 0.78-0.94

Level 3: 0.95-0.95

Level 3: 335-3.35

Level 3: 0.90-0.92

Note. a = single administration, split half internal consistency; b= test-retest stability, consistency of
classification from test to retest, ages 18-44 only; c=intercorrelations of the subtests and index scores;
1=MicroCog Manual. SEM = standard error of measurement; Subtest scores included total scores for Numbers
Forward, Numbers Reversed, Alphabet, Wordlist 1&2, Story 1&2 Immediate & Delayed Recall, Clocks,
Tic Tac, Analogies, Math, Object Match A&B; Level 1 Index includes Attention/Mental Control, Memory,
Spatial Processing, Reasoning/Calculation, Reaction Time; Level 2 Index includes Information Processing
Speed & Information Processing Accuracy; Level 3 Index includes General Cognitive Proficiency &
General Cognitive Functioning.
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Table 2 shows the split half internal consistency reliability coefficients for most tests
except those where this was not possible due to presentation format and/or task requirements.
The average subtest reliability coefficients range from 0.58 to 0.98, with a mean of 0.76.
Average reliability coefficients for index total score and response time ranged from 0.78 to 0.95
(Powell et al., 2004).
Test-retest reliability was measured by testing participants twice (Time 2 at seven
months) and finding how consistently the participants were classified as Below average, Low
Average, Average, and Above Average at both the subtest and index score levels. The
agreement from test to retest were very stable and showed little practice effects (Powell et al.,
2004). In 2006, Raymond et. al published reliable changes indices and regression based
equations to allow for administrators to account for practice effects when tests are repeated at
two weeks and three months in healthy individuals over the age of 50.
Validity of the MicroCog. Data from validity studies of subtest and Level 1 index scores
support the validity of the MicroCog. For example, Memory subtests correlated at 0.66.
Validity for Level 2 Index scores are as follows: For Information Processing Accuracy, of the 10
subtests total scores that could be analyzed, 9 factor loadings were above 0.50. For Information
Processing Speed, of the 8 subtest response times in the analysis, 7 factor loadings were above
0.50. Another factor analytic study of the MicroCog in a sample of participants suffering from
substance abuse confirmed a two factor model of the MicroCog the authors identified as the
Information Processing Accuracy and Information Processing Speed scores (Level 2 Indices)
(Lopez, Sumerall, & Ryan, 2002). For both factors, factor loadings from the corresponding
subtest scores were 0.50 or above for 16 out of the 20 subtests.

21
Criterion validity studies provide evidence for how well the MicroCog accurately
classifies participants as a healthy control or as a member of their respective clinical group. The
MicroCog developers and Elwood (2001) summarized a series of studies comparing the
performance of clinical groups to nonclinical groups. Clinical groups included dementia
(diagnosed as probable Alzheimer’s, or multiinfarct or vascular dementia), lobectomy, lupus,
schizophrenia, mixed psychiatric/neurologic groups. Altogether, using Level 1 Index scores as
discriminant variables, the correct classification rates for clinical groups (besides Major
Depression) ranged from 65% (lupus) to 92% (dementia). One such study (Green, Green,
Harrison, & Kutner, 1994) included 52 patients with mild cognitive impairment (47 diagnosed
with probable Alzheimer’s disease and five diagnosed with multi-infarct or vascular dementia).
The mean scores for all index scores of the non-impaired controls were in the Average range.
The mean scores for the clinical group ranged from 70.7 to 84.9 (one to two deviations from the
normative mean). The authors calculated that with a 10% prevalence rate of dementia, the
sensitivity and specificity would yield a PPP of .70 and an NPP of .98. In a study of Gulf War
veterans, the MicroCog correctly classified 27 out of 31 veterans with mild to no cognitive
impairment based on standardized neuropsychological tests (Holliday & Costello, 1997).
There is good convergent validity for the MicroCog. For example, for Level 1 Index
scores, the Attention/Mental Control Index score correlated with the Wechsler Memory ScaleRevised Attention/Concentration Index (WMS-R-AC) at 0.57, the Memory Index score
correlated with the WMS-R-Delayed Recall at 0.46, the Reasoning/Calculation Index Score
correlated with the Shipley Institute of Living Scale Abstraction T-Score at 0.56, and Spatial
Processing correlated with Dementia Rating Scale-Construction subtest at 0.37. The IPA Index
score correlated at 0.54 with the Full Scale Intelligence Quotient of the Wechsler Adult
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Intelligence Scale-Revised (WAIS-R). The IPS correlated with the Performance Intelligence
Quotient of the Wechsler Adult Intelligence Scale-Revised at 0.31. Other authors have found
similar findings in studies with older adults (Green et al., 1994; Helmes & Miller, 2006; Johnson
& Rust, 2003) and individuals with brain injuries (O'Keefe, 1997).
Study Objectives and Hypotheses
The MicroCog is a reliable, valid measure of cognitive functioning and has been used in a
variety of patient populations. This, along with its ease of administration, makes the MicroCog a
good candidate instrument for use as an outpatient screening tool for cognitive impairment,
including mental processing speed, in participants with RRMS. There is no research that uses
the MicroCog to assess cognitive function in RRMS populations.
Objectives
The primary objective of this study is to use the MicroCog to assess cognitive function in
clinically definite RRMS sample compared to matched healthy controls.
Hypothesis 1
RRMS participants will have worse cognitive function compared to controls.
Primary Outcome: RRMS participants will have worse cognitive function compared to
controls on all MicroCog Level 2 and 3 Index Scores.
Secondary Outcome: RRMS participants will have worse cognitive function on Level 1
Index scores compared to controls.
Hypothesis 2
Clinical variables (clinical status, symptoms of depression, disease duration) will be
associated with worse cognitive performance on MicroCog Level 2 and 3 index scores. That is
more impaired clinical status, higher severity of depression symptoms, and longer disease
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duration will be associated with cognitive impairments. Sex will not be associated with worse
cognitive performance on the MicroCog.
Hypothesis 3
The MicroCog Information Processing Speed (Level 2) Index score will be associated
with a paper-and-pencil tests of processing speed commonly used in assessment of participants
with RRMS, the Symbol Digit Modalities Test and the Paced Auditory Serial Addition Test.
Methods
Twenty-eight participants between the ages of 18-65 diagnosed with RRMS as defined by
McDonald criteria (Polman, et al., 2011) were recruited and screened by a Board Certified
Neurologist (John F. Foley, MD) from the Rocky Mountain Neurological MS Clinic in Salt Lake
City, Utah. RRMS participant recruitment took place within the neurology clinic. Twenty-nine
controls were recruited within the clinic (i.e. family members/friends of participants and
researchers, office staff). Study inclusion criteria were diagnosis of RRMS, age 18 to 65 years,
and English speaking. Study exclusion criteria included: non-English speaking, visual deficits,
hearing deficits, dense dominant limb paralysis (that would interfere with test administration),
history of drug or alcohol abuse, prior cognitive impairment or developmental disabilities (e.g.,
traumatic brain injury, stroke resulting in cognitive deficits, Parkinson’s disease, Huntington’s
disease, Alzheimer’s disease). Two of the 28 RRMS recruited were not included in the final
analyses because after data collection it was confirmed through their medical chart that the
participant had a medical or substance use condition that could confound results, including brain
aneurysm and drug/ alcohol abuse with history of multiple concussions.
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Demographic and Medical Variables
Demographic and medical history was collected and included sex, age, date of birth, and
years of education. Medical history included comorbid medical disorders (cardiovascular
disease, diabetes, etc.), medications, prior neurologic disease (e.g. traumatic brain injury), and
radiology reports from prior magnetic resonance imaging (MRI) scans. Medical history specific
to RRMS (including disease duration and type of MS) was also collected. Disease duration was
defined as date of symptom onset to date of data collection. This was reported by the participant
and also confirmed through their medical chart. In the event the participant’s report was
discrepant from their medical chart, the medical chart date was used. In the event no
information on symptom onset was in their medical chart, the participant’s report was used.
Only the year of symptom onset was taken into account, not month or date.
Depression
This study utilized the Beck Depression Inventory–II (BDI-II; Beck, Steer, & Brown,
1996) as a measure of depression symptoms. This instrument consists of 21 statements
describing somatic and cognitive-affective symptoms of depression. Scores range from 0 to 63
with higher scores reflecting more severe depressive symptoms. A review of the psychometric
properties of the BDI revealed a mean coefficient alpha for internal consistency of 0.86 in
psychiatric populations. The review also revealed high correlation coefficients with the
Hamilton Rating Scale for Depression (HRSD) (r=0.72) and clinical ratings (r=0.73). One week
test-retest reliability is high (r=0.93) (Beck, Steer, & Carbin, 1988). The BDI-II is the most
commonly used depression scale in MS associated depression (Arnett et al., 2005). Sacco et al.
(2016) indicated the BDI-II has good internal consistency and good convergent and divergent
validity with MS patients.
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Clinical Status Measure – Multiple Sclerosis Functional Composite
The National Multiple Sclerosis Society’s Multiple Sclerosis Functional Composite
(MSFC) task was used as a measure of clinical status (Fischer et al., 2001). The MSFC was
developed as part of a task force as an outcome measure that has good correlation with
biologically relevant clinical dimensions, good reliability, and an ability to show change over
time (Cutter et al., 1999). The MSFC includes a the timed 25-foot walk (T25FW) to measure
leg function, the timed nine-hole peg test (9HPT) to measure upper extremity function, and the
3-second version of the PASAT to measure neuropsychological function. The MFSC has high
intrarater and interrater reliability (0.97 and 0.96 respectively over four administrations) with
both RRMS and SPMS participants (Cohen, et al., 2000; Fischer et al., 1999). The MFSC
correlates with quality of life measures including subtests of the Multiple Sclerosis Quality of
Life Inventory (MSQLI) (Sickness Impact Profile (r=-0.62); Medical Outcomes Study 36-Item
Short-Form Health Survey (r=0.41)) (Miller, Rudick, Cutter, Baier, & Fischer, 2000).
For the current study raw scores on the three component subtests were converted into zscores based on the means of the healthy control group. The average of a participant’s three zscores is the participant’s overall MSFC z-score.
Processing Speed
The Symbol Digit Modalities Test, a paper-pencil test of processing speed and attention,
was administered (Smith, 1973). The SDMT presents a series of nine abstract symbols, each of
which is paired with a single digit in a key at the top of a sheet of paper. The remainder of the
paper has a pseudo-randomized sequence of the nine symbols and the subject is required to scan
the key and respond with the digit associated with each symbol as quickly as possible. The
outcome variable for the SDMT is the total number of items correct within 90 seconds.
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Administration procedures were followed as put forth by the SDMT manual. Standard scores
were derived based on the age and education corrected normative data in the SDMT manual.
The SDMT has test-retest correlations ranged from 0.82 to 0.95 when administered
monthly over a five month period in a sample of participants with clinically definite MS and
controls (Benedict et al., 2008). The SDMT has been found to correlate strongly with magnetic
resonance imaging (MRI) measures of disease burden in MS (Benedict et al., 2004;
Christodoulou et al., 2003).
Effort
In order to ensure that participants are trying their best on the cognitive tests, Reliable
Digit Span (RDS) was used to assess effort (Greiffenstein, Baker, & Gola, 1994). RDS was
calculated for each participant by summing the longest string of digits repeated without error
over two trials for both forward and backward conditions on MicroCog subtests Numbers
Forward and Numbers Backward subtests. An RDS of 7 or less qualified as possible poor effort
(Lezak et al., 2012).
MicroCog
The MicroCog was administered on a desktop computer by the study investigator (S.M.).
Standardized instructions were followed as put forth by the MicroCog manual. Participants were
monitored during testing and behavioral observations (e.g. whether able to sustain attention to
test without encouragement) were made during administration to aid in determining whether the
MicroCog is well suited to be taken without ongoing assistance from the examiner. Participants
were administered the 18 subtest standard form of the instrument, with an administration time of
60 minutes. The subtest descriptions are below.
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MicroCog subtest descriptions. The subtests from the MicroCog standard form are
shown below along with the description of each task (Powell et al., 2004).
1. Timers 1: Participants presses the Enter key in response to auditory signals, visual
signals, and visual signals preceded by auditory signal (5 of each type of signal).
2. Address: On the screen a name and address are presented. Participants are told to
memorize address for questions later on in the test.
3. Clocks: For each trial participants are shown a clock face with an hour and minute
hand. The participant must choose from 5 digital choices which is the correct time on
the stimulus clock.
4. Story 1-Immediate Recall: A story will be presented and participants must
immediately recall the story as demonstrated by recognition of details of the story in 6
multiple choice questions.
5. Math: Eight math problems are answered using the numeric keypad and include
addition, multiplication, and division problems. The participant may not use paper.
6. Tic Tac 1: A 3x3 block matrix is presented. Three to five blocks within the matrix
contain a colored square. After the stimulus is removed from the screen, the
participant must reproduce the pattern using the numeric keypad.
7. Analogies: The participant answers multiple choice questions on verbal analogies.
8. Numbers Forward: The participant is shown a series of single digits, up to 9 digits.
After the digits are off the screen, the participant enters in the digits (in order) on the
numeric keypad.
9. Story 2-Immediate Recall: Same description as Story 1 but with different content.
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10. Wordlist 1: The participant is asked to press Enter when a word appears from an
instructed category (e.g. Look for words that are items on clothing). There are four
categories total.
11. Wordlist 2: The participant is asked to press Enter when a word appears that was
from one of the four categories in Wordlist 1.
12. Numbers Reversed: The participant is shown a series of single digits, up to 9 digits.
After the digits are off the screen, the participant enters in the digits (in reverse order)
on the numeric keypad.
13. Address: The participant is asked to choose the name and address previously
presented in the test.
14. Object Match: The participant is shown a set of four stimuli (figures) and asked to
choose the number of the figure that does not match the other figures.
15. Story 1 Delayed Recall: The participant is asked multiple choice questions based on
Story 1 content.
16. Alphabet: The participant is shown a series of letters. The subject is asked to pick out
letters in alphabetical order by pressing Enter whenever the next letter in the alphabet
appears.
17. Tic Tac 2: Same description as Tic Tac 1 with different stimuli.
18. Story 2 Delayed Recall: The participant is asked multiple choice questions based on
Story 2 content.
19. Timers 2: Same description as Timers 1.
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Statistics
Statistical analyses were conducted using IBM SPSS Statistics Version 23. Given the
high number of planned statistical analyses and the low sample size, a Bonferroni correction was
calculated. Alpha level p=0.001 was utilized for all results interpretation.
Descriptive statistics for demographic, medical, psychological, cognitive data (i.e.
MicroCog scores) and physical function were conducted. Continuous data were analyzed using
independent samples t-tests and categorical data were analyzed using Chi-square analysis.
Hypothesis 1 (Group differences in Level 1, 2, and 3 MicroCog performance)
Primary outcome: An analysis of covariance (ANCOVA) test was calculated to
determine if there was significant difference between the RRMS and control group performances
for all Level 2 and 3 MicroCog scores. Depression was included as a covariate in the analysis.
Secondary outcome: An analysis of covariance (ANCOVA) test was calculated to
determine if there were significant performance differences between RRMS and control groups
for all Level 1 MicroCog scores. Depression was a covariate in the analysis.
Hypotheses 2 (Covariates of MicroCog performance)
Pearson’s correlation was calculated to assess the relationships between MicroCog scores
(Level 2 and 3) clinical variables (MSFC score, disease duration, and depression). A point
biserial r was be calculated to assess the relationship between MicroCog scores and sex.
Hypothesis 3 (Correlation between MicroCog and traditional processing speed measure)
Pearson’s correlation was calculated to assess the relationships between SDMT and
PASAT performance and MicroCog Information Processing Speed (IPS) index score.
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Results
Demographic and Medical Variables
Descriptive statistics for demographic and clinical variables are reported in Table 3. For
the RRMS group the mean age was 48.96 (SD=11.23) and the mean number of years of
education was 14.65 (SD=2.76). Approximately 76% of the RRMS group was female. For the
control group the mean age was 35.9 (SD=11.79), mean years of education was 16.07 (SD=2.2),
and 72% of the sample were female. There were no differences between the RRMS and control
groups for female sex (t(53)=-2.11, p=.04) or education (ᵪ²(1)=0.15, p=0.70). There was a
significant difference between RRMS and control group for age with the RRMS group being
older (t(53)=4.19, p=0.00). Radiological findings for each RRMS participant are listed in Table
4. There were some participants whose most recent radiology study did not include discussion of
white matter lesion distribution. In these cases (identified in the table) the research coordinator
from Rocky Mountain Neurological MS Clinic reviewed the participant’s prior radiology studies
and provided a summary statement of the participant’s distribution of white matter lesions. All
brain imaging indicated some degree of white matter disease was present. Three participants
with RRMS had generalized atrophy. Five participants had widespread white matter disease.
Some imaging reports indicated white matter lesions in specific brain structures including
periventricular white matter (n=8; specific areas included infratentorial and supratentorial
regions, left hemisphere, frontal horn of the right and left lateral ventricle), corpus callosum or
pericallosal areas (n=4; specific areas included left brachium pontes, and frontal, parietal,
posterior temporal and occipital lobes), bilateral basal ganglia (n=1), brainstem and cerebellum
(n=1), left subcortical frontal lobe (n=1), left temporo- or temporoparietal subcortical area (n=2),
right anterior medulla (n=1), body of fornix (n=1), and optic nerve (n=1).
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Table 3
Descriptive Statistics for demographic and clinical variables
Mean; Standard Deviation

Sample Size and Percentage of

RRMS

Ctl

Significance

Sample
RRMS

Ctl

(n=26)

(n=29)

testing

n (%)

n (%)

48.96 ±11.23

35.9 ±11.79

t (53) = 4.19,

18-29 years

1 (3.9%)

12 (41.4%)

p=.000*

30-39

5 (19.2%)

7 (24.1%)

40-49

6 (23.1%)

5 (17.2%)

50-59

8 (30.1%)

3 (10.3%)

60-65

6 (23.1%)

2 (6.9%)

t(53) = -2.11,

<12 years

1 (3.8%)

0%

p=.04

12

7 (26.9%)

3 (10.3%)

12-15

6 (23.1%)

4 (13.8%)

16

5 (19.2%)

11 (37.9%)

17+

7 (26.9%)

11 (37.9%)

0-5 years

3 (11.5%)

NA

Duration

6-10

4 (15.4%)

(mean ± SD)

11-15

7 (26.9%)

16 -20

6 (23.1%)

21+

6 (23.1%)

Descriptive

Age
(mean ± SD)

Sex (Female)

23.1, 76.9

27.6, 72.4

N, %
Education

p=0.69
14.65 ± 2.76

16.07 ± 2.2

(mean ± SD)

Disease

ᵪ²(1) = 0.16,

16.42 ± 9.86

NA

NA

Note. Ctl=control group; RRMS=relapsing remitting multiple sclerosis group; MSFC = Multiple Sclerosis
Functional Composite, NA = not applicable, Percentage=percentage within each subgroup, SD=standard deviation,
*significance≥0.001.
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Table 4
Radiology reports – most recent for each RRMS participant (one participant per cell).
MS
Participant

WM
disease
present

Generalized
Atrophy

Widespread
WM disease

Periventricular
WM *

Corpus
callosum or
pericallosal
areas**

Specific brain structures with WM lesions
Bilateral
Brainstem
Left
Left
basal
and
subcortical
temporoganglia
cerebellum frontal lobe
or
temporoparietal
subcortical
area

Right
anterior
medulla

Body
of
fornix

Optic
nerve

1
x
x
2
x
3
x
x
4
x
x
5
x
x
x
x
6
x
x
7
x
x
8
x
x
x
9
x
x
x
10
x
x
11
x
x
12
x
x
13
x
x
14
x
x
15
x
x
16
x
17
x
x
x
18
x
x
x
x
19
x
x
x
20
x
21
x
x
22
x
23
x
x
24
x
x
25
x
x
26
x
Note. x=feature was described on most recent MRI scan or within summary statement of white matter lesion distribution that was provided by research coordinator of Rocky
Mountain Neurological MS Clinic; *Specific periventricular areas included infratentorial and supratentorial regions, left hemisphere, frontal horn of the right and left lateral
ventricle; ** Specific areas included left brachium pontes, and frontal, parietal, posterior temporal and occipital lobes; WM=White matter.
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Effort
No control participants exhibited poor effort. Two RRMS participants exhibited
questionable effort. One of these participants did not respond accurately to any Numbers
Backward trials but was correct to five digits for Numbers Forward. This participant’s
MicroCog indices (Level 1, 2, and 3) ranged from 64 to 96, suggesting good effort on testing
generally, and therefore their data was included in the final analysis. The second participant
performed poorly on most indices (Level 1, 2, and 3 scores ranged from 61 to 75). In order to
learn how removing this participant might influence results, the analysis for the first hypothesis
(ANCOVA for Level 2 and 3 indices) was repeated with the participant’s scores removed.
Removal of the participant did not change the results. Therefore, the participant’s data was
included in the final analysis. Disease duration for this individual was 30 years which may
explain the lower test scores.
Depression
Table 5 includes information for scores on the BDI-II, MSFC, and SDMT. The average
BDI-II score for the RRMS group was 17.71 (SD=10.40). This score falls within the “mild”
range of depression (Beck, Steer, & Brown, 1996). The average BDI-II score for the control
group was 5.72 (SD=5.12). This average score falls below the cutoff for depression. The
RRMS group had a higher average BDI-II score than the control group (t(53)=-5.47, p=.000).
Fifteen (57.7%) of the RRMS participants were on anti-depressants, including fluoxetine,
buproprion, duloxetine, citalopram, and sertraline. Of those on antidepressants, utilizing BDI-II
cutoff scores, five patients scores were below the cutoff for depression symptoms (e.g. no
symptoms of depression) , three had mild symptoms, five had moderate symptoms, and two had
severe symptoms. Of those not on antidepressants, three participants’ scores were below the
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cutoff for depression symptoms (e.g. no symptoms of depression), four had mild symptoms,
three had moderate symptoms, and one had severe symptoms. Overall, there was no obvious
differences between depression symptoms levels based on whether participants were on
antidepressants.
Clinical Status Measure – Multiple Sclerosis Functional Composite
There was one RRMS participant who did not want to complete the PASAT because they
found the test too anxiety provoking. The test was discontinued and this participant’s MSFC
total score and PASAT were excluded from analyses (9-HPT and TFFW were retained). The
average MSFC z-score for the RRMS group was -1.97 (SD=1.22). The average 9-HPT z-score
was -1.70 (SD=1.20), the average TFFW was 0.00 (SD=1.00), and the average PASAT was 1.86 (SD=1.35). The average MSFC z-score for the control group was 0.00 (SD=0.70). The
average 9-HPT z-score was -1.70 (SD=1.20), the average TFFW was -2.28 (SD=2.95) the
average PASAT was -1.70 (SD=1.20). The RRMS group had a lower average MSFC score than
the control group (t(53)=-7.42, p=.000).
Processing Speed
The mean SDMT score for both groups was in the Average range. The average SDMT zscore for the RRMS group was -0.65 (SD=0.88). The average SDMT z-score for the control
group was 1.05 (SD=0.87). The mean for the RRMS group was significantly lower than the
control group mean (t(53)=-7.19, p=.000).
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Table 5
Descriptive Statistics for BDI-II, MSFC, and SDMT
Mean; Standard Deviation
Test

BDI-II

RRMS

Ctl

Significance

(n=26)

(n=29)

testing

17.71 ± 10.40

5.72 ± 5.12

t(53) = -5.47,

(mean ± SD)

MSFC

0.00 ± 0.70

(mean ± SD)

-0.65 ± 0.88

(mean ± SD)

1.05 ± 0.87

Scores𝒂
range

RRMS

Control

n (%)

n (%)

0 to 5

5 (19.2%)

18 (62.1%)

6 to 10

1 (3.8%)

8 (27.6%)

11 to 20

11 (42.3%)

2 (6.9%)

21 to 30

6 (23.1%)

1 (3.4%)

31 to 40

2 (7.7%)

0%

41+

1 (3.8%)

0%

t(53) = -7.63;

-5.0 to -2.5

8 (30.8%)

0%

p=0.00*

-2.4 to -1.5

7 (26.9%)

1 (3.4%)

-1.4 to -0.5

9 (34.6%)

6 (20.7%)

-0.4 to 0.5

2 (7.7(%)

14 (48.3%)

0.6 to 1.5

0

8 (27.6%)

-2.4 to -1.5

3 (11.5%)

0%

-1.49 to -0.5

12 (46.1%)

1 (3.4%)

-0.49 to 0.5

8 (30.8%)

7 (24.1%)

0.51 to 1.50

3 (11.5%)

13 (44.8%)

1.51 to 2.6

0%

8 (27.6%)

p=.000*

-1.90 ± 1.12

SDMT

Sample Size and Percentage

t(53) = -7.19;
p=0.00*

Note. BDI-II = Beck Depression Inventory-II, Ctl=control group, RRMS=relapsing-remitting multiple sclerosis
group; MSFC = Multiple Sclerosis Functional Composite, Percentage = percentage within each subgroup,
SD=standard deviation, SDMT =Symbol Digit Modalities Test, *significance ≥ 0.001, a=BDI-II scores are raw
scores, MSFC and SDMT scores are z-scores.

MicroCog
Table 6 includes descriptive statistics for MicroCog scores. Table 7 includes descriptive
information for qualitative descriptors of MicroCog performance. For all index scores neither
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the RRMS or control group mean score fell below the Average range. The RRMS group
typically performed in the Average to Low Average range and the control group typically
performed in the Average to Above Average range. Sixteen RRMS participants (61.5%) had one
or more index scores in the Below to Low Average range (i.e., scaled score of 84 or less), and
seven of these participants (27%) had five or more scores in this range. Eleven control
participants (38%) had one or more index scores in this range, and only one (3%) had over three
scores in this range. Mean differences in RRMS and control performance for each index score
ranged from 4 to 17 points.

Cognitive impairment was defined as two or more index scores

being 1.5 standard deviations below the mean or lower, or at least one index score two standard
deviations below the mean. Using this criteria, eight (30.7%) of the RRMS participants were
impaired and two control participants (6.8%) were impaired on the MicroCog battery.
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Table 6
Descriptive Statistics for Level 1, 2, and 3 index scores for RRMS and control groups
RRMS
Index

Ctl

Median

Mean

SD

Median

Mean

SD

GCF

94.5

90.04

14.35

106

104.86

9.39

GCP

88.5

88.46

14.03

108

106.03

10.42

IPS

95.5

95.85

13.46

112

110.65

8.68

IPA

90.5

88.19

12.95

100

97.55

12

Attention

96.5

95.85

13.17

104

103.79

11.54

Memory

101

96.38

16.02

113

111.17

13.46

Spatial

99

96.85

13.62

109

106.48

10.71

90.5

87.12

17.36

102

101.83

13.47

96

93.69

14.15

99

98.52

10.09

Reasoning
Reaction Time

Note. Ctl=control group; Level 1 Index includes Attention/Mental Control, Memory, Spatial Processing,
Reasoning/Calculation, Reaction Time; Level 2 Index includes Information Processing Speed (IPS) &
Information Processing Accuracy (IPA); Level 3 Index includes General Cognitive Proficiency (GCP) &
General Cognitive Functioning (GCF); RRMS= relapsing-remitting multiple sclerosis group; SD=standard
deviation; significance*=p≤.001.

38
Table 7
Percentage of samples by qualitative descriptor for Level 1, 2, and 3 MicroCog scores
Scaled

Above Average

Average

Low Average

Below Average

Score
RRMS

Ctl

RRMS

Ctl

RRMS

Ctl

RRMS

Ctl

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

GCF

0

3 (10%)

18 (69%)

25 (86%)

4 (15%)

1 (3%)

4 (15%)

0

GCP

0

5 (17%)

18 (69%)

22 (76%)

5 (19%)

2 (7%)

3 (11%)

0

IPS

1 (4%)

8 (28%)

18 (69%)

20 (69%)

7 (27%)

1 (3%)

0

0

IPA

0

0

15 (58%)

25 (86%)

8 (31%)

3 (10%)

3 (11%)

1 (3%)

Attention

1 (4%)

5 (17%)

21 (81%)

23 (79%)

2 (8%)

1 (3%)

2 (8%)

0

Memory

2 (8%)

14 (48%)

17 (65%)

15 (52%)

6 (23%)

0

1 (4%)

0

0

7 (24%)

16 (61%)

17 (59%)

5 (19%)

5 (17%)

5 (19%)

0

2 (8%)

8 (28%)

20 (77%)

20 (69%)

3 (11%)

1 (3%)

1 (4%)

0

0

0

21(81%)

26 (90%)

3(11%)

3 (10%)

2(8%)

0

Reasoning
Spatial
Reaction
Time

Note. n=number of participants; %=percentage of sample within qualitative descriptor category rounded to nearest
ones unit; Ctl=Control group; Level 1 Index includes Attention/Mental Control, Memory, Spatial Processing,
Reasoning/Calculation, Reaction Time; Level 2 Index includes Information Processing Speed (IPS) & Information
Processing Accuracy (IPA); Level 3 Index includes General Cognitive Proficiency (GCP) & General Cognitive
Functioning (GCF); RRMS=relapsing-remitting multiple sclerosis group.

Hypothesis 1: Group differences in Level 1, 2, and 3 MicroCog performance
Level 2 and 3 outcomes. Visual inspection of histograms for Level 2 and 3 outcome
scores suggested normality assumptions were sufficiently met so that analyses could proceed.
Outliers were fenced to the median ± two interquartile range for the following variables: GCP,
IPS, and IPA (which improved kurtosis and skewness in these cases). Z-scores for skewness and
kurtosis were calculated for distributions of the RRMS and control group separately and then the
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groups together. There were no significant z-scores for kurtosis. Two variables had significant
z-scores (p=.05) at 1.96 for skewness. These included GCF (groups combined only, negative
skew, z=2.94) and IPA (control only, negative skew, z=2.35). These violations were considered
minor enough that analysis could proceed.
Preliminary data screening indicated there was one outlier for depression that was fenced
(a score of 45 was outside two interquartile ranges of the median and was fenced to 41). The
histogram for depression (i.e., BDI-II scores) had a positive skew. Removing the outlier
improved normality of the histogram.
To assess for violations of the homogeneity of regression (whether there was an
interaction between the RRMS and control group and the covariates), a preliminary ANCOVA
was calculated with a custom model that included a covariate by group interaction term. There
were no statistically significant interactions for any of the Level 2 or 3 outcome variables for
depression (p-values were 0.06 (GCF), 0.08 (GCP), 0.26 (IPS), and 0.07 (IPA)), and therefore
the final ANCOVA reported does not include an interaction term.
The Levene test was performed to assess violations of homogeneity of variance. The
results of GCF and IPS variables were significant. In these cases, an independent samples t-test
with equal variance not assumed was calculated in help ensure the violation did not impact
results (GCF: t(42.3)=-4.48, p=0.00, two-tailed; IPS: t(41.91)=-4.90, p=0.00). The results
aligned well enough with the ANOVA results (discussed below) that we proceeded with the
ANCOVA analysis for these variables.
An ANOVA was calculated for all Level 2 and 3 outcome variables to learn about group
differences without controlling for depression. There was a statistically significant difference for
RRMS and control groups for three out of four outcome variables: GCF (F (1, 53) = 20.96,
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p=0.000), GCP (F (1, 53) = 26.18, p=0.000), IPS (F (1, 53) = 24.00, p=0.000). There was not a
statistically significant difference for IPA (F (1, 53) = 7.74, p=0.007).
An ANCOVA with depression as a covariate was calculated for each outcome variable.
A Type III computational method was used because the primary focus was between group
differences in MicroCog scores (therefore order of entry for the covariate was less important).
The main effects for RRMS were not significant for GCF and IPA scores (Table 8). The main
effects were significant for GCP and IPS. The strength of the association between group
membership (i.e., RRMS) and outcome variables (e.g., GCF) as measured by partial eta squared
(the amount of variance in outcome scores predictable by group membership after controlling for
covariates) ranged from 0.05 to 0.22.
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Table 8
ANCOVA for Level 1, 2, and 3 MicroCog Index Scores (RRMS as fixed factor, age and
depression as covariates)
MicroCog Index Score

F

Significance (p-value)

Partial Eta Squared

(df=1, 55)
GCF

10.18

0.002

0.16

GCP

14.12

0.00*

0.21

IPS

14.45

0.00*

0.22

IPA

2.77

0.10

0.05

Attention

1.67

0.20

0.03

Reasoning

6.96

0.01

0.12

Memory

9.55

0.003

0.15

Spatial

2.83

0.10

0.05

Reaction Time

0.28

0.60

0.00

Note. Level 1 Index includes Attention/Mental Control, Memory, Spatial Processing, Reasoning/Calculation,
Reaction Time; Level 2 Index includes Information Processing Speed (IPS) & Information Processing Accuracy
(IPA); Level 3 Index includes General Cognitive Proficiency (GCP) & General Cognitive Functioning (GCF);
significance*=p≤.001..

Adjusted and unadjusted group means for the outcome variables are provided in Table 9.
The adjusted means are estimates of what the outcome variable might have been if the treatment
groups had been exactly equal on the covariates. For all outcome variables, the adjusted means
were closer together for the groups than for the unadjusted means. That is, the means were more
similar for the two groups when controlling for depression.
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Table 9
Unadjusted and Adjusted Mean Scores
Outcome Variable

Unadjusted Mean

Adjusted Mean

RRMS

Ctl

RRMS

Ctl

GCF

90.04

104.86

90.97

104.03

GCP

88.46

106.03

89.43

105.16

IPS

95.85

110.65

95.96

110.55

IPA

88.19

97.55

89.40

96.46

Attention

95.85

103.79

97.17

102.60

Reasoning

87.12

101.83

87.51

101.47

Memory

96.38

111.17

95.95

111.56

Spatial

96.85

106.48

98.27

105.21

Reaction Time

93.69

98.52

95.09

97.26

Note. Ctl=control group; Level 1 Index includes Attention/Mental Control, Memory, Spatial Processing,
Reasoning/Calculation, Reaction Time; Level 2 Index includes Information Processing Speed (IPS) &
Information Processing Accuracy (IPA); Level 3 Index includes General Cognitive Proficiency (GCP) &
General Cognitive Functioning (GCF); RRMS=relapsing-remitting multiple sclerosis group.

Level 1 outcomes. Visual inspection of histograms for Level 1 Index scores
(Attention/Mental Control (Attention), Memory, Reasoning/Calculation (Reasoning), Spatial
Processing (Spatial), and Reaction Time (RT)) suggested normality assumptions were
sufficiently enough met so that analyses could proceed. There were some variables with a slight
non-normal distribution, typically with a random or negative skew. Outliers were fenced to the
median +/- two interquartile ranges for the Spatial variable (which improved kurtosis and
skewness). Z-scores for skewness and kurtosis were calculated to better understand any
violations or normality. These were calculated for distributions of the RRMS and control group
separately and then the entire sample together. There were no significant z-scores for kurtosis.
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Three variables had significant z-scores (p=.05) at 1.96 for skewness. These included Attention
(groups combined, negative skew, z=2.69; RRMS only, negative skew, z=2.08), Spatial (groups
combined, negative skew, z=2.85; control only, negative skew, z=2.06), Reaction Time (groups
combined, negative skew, z=3.56; control only, negative skew, z=-2.43; RRMS only, negative
skew, z=-2.15). These violations were considered minor enough that analysis could proceed.
The Levene test assessed homogeneity of variance. There were two variables for which
the assumption was violated, Reasoning and RT. In these cases, a t-test where equal variance
was not assumed was performed. For Reasoning, the mean scaled scores differed significantly,
t(47.05)=-3.48, p=0.001, two-tailed. For RT, the mean scaled scores did not differ significantly,
t(44.68)=-1.44, p=0.16, two-tailed. This was consistent with the ANOVA results for these
variables and therefore we proceeded with ANCOVA analyses for these scores.
To assess for violations of the homogeneity of regression a preliminary ANCOVA was
calculated with a custom model that included a covariate by group interaction term. There were
no statistically significant interactions for any of the Level 1 outcome variables (p-values were
0.29 (Attention), 0.25 (Reasoning), 0.18 (Memory), 0.08 (Spatial), and 0.72 (RT)), and therefore
the final ANCOVA reported does not include an interaction term.
An ANOVA was calculated for all Level 1 outcome variables without controlling for
depression. There were significant differences found between the RRMS and control group for
two Level 1 scores: Memory (F (1, 53) = 13.83, p=0.000) and Reasoning (F (1, 53) = 12.47,
p=0.001). The RRMS and control groups did have not statistically significant differences for
the other three Level 1 scores: Attention (F (1, 53) = 5.69, p=0.021), Spatial (F (1, 53) = 8.60,
p=0.005), and Reaction Time (F (1, 53) = 2.15, p=0.148).
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An ANCOVA was calculated for each Level 1 outcome variable with depression as a
covariate. A Type III computational method was used. The main effects for the RRMS and
control groups were not significant for any Level 1 score (Table 8, see above). The strength of
the association between group membership and outcome variables (e.g., Memory) as measured
by partial eta squared ranged from 0.00 to 0.15.
Adjusted and unadjusted group means for the outcome variables are listed in Table 9. For
all outcome variables, the adjusted means were closer together for the groups than for the
unadjusted means.
Hypothesis 2: Covariates of MicroCog Performance
Variables in this portion of the analysis (MSFC score, BDI-II, and disease duration) were
screened for violations of normality assumptions. MSFC had a slight negative skew to its
distribution but it was considered normal enough that analysis could proceed. There was one
outlier for MSFC and this was fenced because this participant’s score was low due to his being in
a wheelchair. This improved normality for the distribution. As noted above, the histogram for
BDI-II scores had a positive skew. One outlier was fenced which improved normality. The
histogram for disease duration was approximately normal. There was one outlier that was fenced
to two interquartile ranges from the median (a duration of 44 years was fenced to 40.5 years).
Review of the scatterplots suggested all distributions were approximately linear.
The global score of cognitive and physical disability (MSFC) was significantly correlated
for all Level 2 and 3 index scores with groups combined at p=0.00. The correlation coefficients
(r) for these variables were as follows: GCF=0.61, GCP=0.61, IPS=0.51, IPA=0.49. See Figure
2 for scatter plots of these variables. Correlation coefficients were analyzed separately for each
group to see how relationships between disability and MicroCog performance may differ for the
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RRMS and control groups. For the control group the correlation between MicroCog and
disability decreased (GCF: r=0.18, p=0.36, GCP: r=0.25, p=0.20, IPS: r=-0.07, p=0.73, IPA:
r=0.26, p=0.18). The correlation also decreased for the RRMS group but less so and the
significance level was significant at p≤0.05 for GCF, GCP, and IPA (GCF: r=0.47, p=0.02, GCP:
r=0.40, p=0.05, IPS: r=0.31, p=0.13, IPA: r=0.42, p=0.03).

Figure 2. Scatter plots for MSFC and Level 2 and 3 MicroCog scores.
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Depression (BDI-II) was originally not significantly related to any Level 2 and 3 index
scores except for GCP (GCF: r=-0.39, p=0.003; GCP: r=-0.42, p=0.001; IPS: r=-0.35, p=0.009;
IPA: r=-0.308, p=0.022). There was one bivariate outlier identified for each calculation (this
participant’s BDI-II score was zero and they scored Below Average on MicroCog indices). In
order to learn its influence on these correlations, this participant was removed from this analysis
and correlations were recalculated. With this participant removed, the correlations reached
significance for all but one Level 2 and 3 Index score. (GCF: r=-0.50, p=0.00; GCP: r=-0.52,
p=0.00; IPS: r=-0.43, p=0.001; IPA: r=-0.37, p=0.005). Review of the scatter plots suggested a
negative relationship between depression and MicroCog performance (higher depression scores
were associated with worse cognitive scores). Correlation coefficients were analyzed separately
for the RRMS and control group. For the control group the correlations between Level 2 and 3
index scores and depression were not significant (significance ranged from 0.1 to 0.21 and r
ranged from 0.23 to 0.31). No significant relationships were identified for the RRMS group,
though GCF, GCP, and IPA were significant at p=0.01 (GCF: r=-0.495, p=0.01; GCP: r=-0.49,
p=0.01; IPS: r=-0.27, p=0.20; IPA: r=-0.51, p=0.01).
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Figure 3. Scatter plots for BDI-II and Level 2 and 3 MicroCog scores.

RRMS disease duration did not reach statistical significance for any MicroCog index
score (Figure 4) (GCF: r=-0.47, p=0.01, GCP: r=-0.58, p=0.002, IPS: r=-0.43, p=0.03, IPA: r=0.34, p=0.09). Scatterplots suggested a negative, linear relationship between MicroCog scores
(particularly GCF and GCP) and disease duration.
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Figure 4. Scatter plots for disease duration and Level 2 and 3 MicroCog scores.

As predicted, sex did not account for a significant portion of the variance for Level 2 or 3
index scores. Point biserial r correlations were as follows: GCF: 𝑟𝑝𝑝 =-0.18, p=0.19; GCP: 𝑟𝑝𝑝 =-

0.24, p=0.08; IPS: 𝑟𝑝𝑝 =-0.11, p=0.44; IPA: 𝑟𝑝𝑝 =-0.19, p=0.16.

In sum, both global score of cognitive and physical disability (MSFC) and depression

(BDI-II) were significantly correlated with Level 2 and 3 MicroCog performance when RRMS
and control groups were combined. When the analyses were repeated for the RRMS and control
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groups separately, the correlations were not significant for either group. It is plausible
significant relationships would exist with a larger sample size (more power for the analysis),
particularly for the RRMS group given that for both disability and depression, correlations
reached statistical significance at p<0.05 and there was a linear relationship on scatter plots.
Disease duration was not significantly correlated with MicroCog performance though
scatterplots suggested a negative, linear relationship for GCF and GCP. Sex was significantly
correlated with MicroCog performance.
Hypothesis 3: Correlation between MicroCog and Traditional Processing Speed Measure
Results indicated that the MicroCog IPS scores and SDMT scores were significantly,
positively correlated (r=0.57, p=0.00). See Figure 5 for a scatterplot of this correlation. There
was a wider range of variability in SDMT scores around the average range of IPS scores relative
to Above or Below Average IPS scores. In order further explore the relationship of IPS and
paper-pencil subtests of processing speed, a separate Pearson’s r correlation was calculated for
PASAT and IPS scores. Similar to the SDMT results, the relationship between IPS and the
PASAT was significant (r=0.58, p=0.00). See Figure 6 for a scatterplot of this correlation.
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Figure 5. Correlation between SDMT (paper pencil) and MicroCog IPS (computer based).

Figure 6. Correlation between PASAT (paper pencil) and MicroCog IPS (computer based).
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Post-hoc Analysis
Criterion validity of the MicroCog. Analysis of sensitivity, specificity, positive
predictive value (PPV), negative predictive value (NPV), and receiving operating characteristic
curve (ROC) were performed in order to learn about the criterion validity of the MicroCog in
RRMS. We categorized cognitive impairment in our RRMS sample using performance on
traditional measures of cognitive impairment in MS, the SDMT and the PASAT. A RRMS
participant was considered to have cognitive impairment if they scored either two standard
deviations below the mean on either the PASAT or SDMT, or if they scored 1.5 standard
deviations below the mean or more on both the PASAT and the SDMT. Using this criteria, 12
RRMS participants met criteria for cognitive impairment. All performed two standard deviations
or lower on the PASAT, two participants performed two standard deviations or lower on the
SDMT, and two performed 1.5 standard deviations or lower on the SDMT. See Table 10 for the
results of criterion validity analyses. The MicroCog had a sensitivity value of 58.33 and a
specificity value of 92.96. Calculation of PPV and NPV was based on a prevalence rate of 40%
for cognitive impairment in RRMS. The PPV was 84.49 and NPV was 76.97. The area under
the curve (AUC) for the ROC was 0.76 (95% CI [0.56 to 0.95]). A different approach was taken
where the MicroCog IPS index score was utilized as the predictor variable for cognitive
impairment (as opposed to all MicroCog index scores). The results for the criterion validity of
the IPS (including sensitivity, specificity, PPV, and NPV) were identical to those for overall
MicroCog performance. Because IPS is a continuous variable, the ROC was examined to learn
about cut-scores that would offer the best balance of sensitivity and specificity. A cut-score of
93 on the IPS produced a sensitivity of 66.7 and a specificity of 78.6.
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Table 10
Criterion validity of the MicroCog in RRMS sample
Correctly

Sensitivity

Specificity

PPV

NPV

Classified

(95% CI)

(95% CI)

76.9

58.33

92.86

84.49

76.97

(27.67 to 84.83)

(66.13 to 99.82)

True Positives

False Negatives

True Negatives

False Positives

7

5

13

1

Note. * Cognitive impairment was defined as two or more MicroCog index scores being
1.5 standard deviations below the mean or lower, or at least one index score two standard
deviations below the mean; CI=confidence interval; PPV=positive predictive value;
NPV=negative predictive value.

Hypothesis 1 with age equivalent groups. To better understand the potential influence
of RRMS, age, and depression on differences in MicroCog performance (examined in
Hypothesis 1), post-hoc analyses were performed for Level 2 and 3 index scores with a sample
of participants aged 30 to 53 years old. This range was chosen because it allowed for equivalent
ages between groups with the largest sample size. The sample size for each group was 14 (total
n=28). There was no mean differences in age between groups (t(26)= 1.01, p=.32). There were
no outliers for Level 2 or 3 index scores. There was one outlier for BDI-II scores that was
fenced which improved normality (a score of 45 was fenced to 40). Bonferroni correction was
not applied for this portion of the analyses.
An alternate approach to forming age matched pairs was considered where RRMS and
control group participants were included in the sample if they were the same age. The resulting
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groups of participants were similar enough to the sample described above that the analysis was
not repeated for this sample (ages of RRMS participants ranged from 23 to 61 and there were 14
participants in each group).
Tables 11 shows that a similar pattern emerged in MicroCog scores for this smaller
sample as with the full participant sample. RRMS participants’ mean scores were lower than
controls for each Level 2 and 3 outcome variable. The GCF, GCP, and IPS variables all had
mean differences of about 11 points (RRMS scores were lower). These were significant at
p<0.05, including for GCF (F(1, 27)=5.31), GCP (F(1, 27)=4.61), and IPS (F(1, 27)=5.09). The
IPA mean difference was about 7 points, a non-significant difference (F(1, 27)=1.52). These
results were similar to those of the ANOVA calculations in Hypothesis 1 and because groups
were similar for age in this case, we can be more certain that RRMS and/or depression accounted
for a significant portion of variance in MicroCog performance differences for GCF, GCP, and
IPS.
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Table 11
Group differences in Level 1, 2, and 3 MicroCog score for participants 30 to 53 years in age

RRMS (n=14)

Ctl (n=14)

One-way
ANOVA

Index

Median

Mean

SD

Median

Mean

SD

Mean

F

p-value

Difference
GCF

96.00

91.57

15.13

105.50

102.64

9.68

-11.07

5.31

0.03

GCP

93.00

92.50

14.55

108.00

103.64

11.19

-11.14

4.61

0.04

IPS

99.00

97.43

13.70

108.50

108.78

9.09

-11.35

5.09

0.03

IPA

92.50

89.50

13.56

99.50

96.29

12.52

-6.79

1.52

0.23

Note. n=sample size, Level 2 Index include Information processing speed (IPS) & Information processing accuracy
(IPA); Level 3 Index include General cognitive proficiency (GCP) & General cognitive functioning (GCF);
RRMS=relapsing-remitting multiple sclerosis group; Ctl=control group.

In order to further explore the relationship between depression, RRMS, and MicroCog
performance, an ANCOVA was calculated for each Level 2 and 3 index score, with depression
as a covariate. The tests for homogeneity of regression assumption indicated there was a
significant interaction for RRMS and depression for GCF (p=0.03) and GCP (p=0.02). The
assumption was not violated for IPS (p=0.06) or IPA (p=0.16).
For GCF and GCP variables, a regression was calculated as opposed to an ANCOVA so
that an interaction term for RRMS and depression could be included in the analysis. For GCF
the proportion of variance explained by the entire set of predictor variables included in the
analysis (𝑅2 ) with no interaction term included was 0.32. The overall regression was statistically

significant (F(2,27)=5.85, p=0.008). The main effect for RRMS was not significant (b=-0.15, t-
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score=-0.78, p=0.44). Depression was a significant predictor of GCF scores (b=-0.46, t-score=2.34, p=0.03). The regression was calculated again, this time with an interaction term for
depression and RRMS included in the model. A greater amount of variance was explained by
this model (𝑅2 =0.45) and the overall model was statistically significant (F(3,27)=6.51, p=0.002).

The RRMS by depression interaction term was significant (b=-1.38, t-score=-2.38, p=0.026,

confidence interval= -2.58 to -.183). The corresponding effect size from the portion of GCF
𝑟
uniquely predicted from this interaction was 𝑠𝑠𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖
= 0.19. Overall, the results of the

regression suggested the impact of depression on GCF score differs for the RRMS and control
groups, where a higher number of depression symptoms leads to a sharper decline in GCF score
in the RRMS group. To even further explore this possibility, a one-way ANOVA was
calculated, comparing RRMS participants with high levels of depression (as measured by the
BDI-II; n=6) and RRMS participants with low levels of depression (n=8). “High” levels of
depression were defined as participants with “Moderate” or “Severe” depression (scores of 20 or
greater on the BDI-II). “Low levels” of depression was defined as scores of “Minimal” or
“Mild” depression (scores of 19 or below). The difference between the two groups was
significant (F(1,13)=20.80, p=0.001). Unfortunately, the same comparison could not be
calculated for the control group because there were not enough control participants with “high”
levels of depression symptoms for the analysis.
Similar results were identified for GCP. The proportion of variance explained by the
entire set of predictor variables included in the regression analysis (𝑅2 ) for GCP with no
interaction term included was 0.42. The overall model was statistically significant

(F(3,27)=5.83, p=0.004). An interaction term was then added to the model. The RRMS by
depression interaction term was significant (b=-1.48, t-score=-2.41, p=0.02, confidence interval=
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-2.75 to -.21). The corresponding effect size from the portion of GCP uniquely predicted from
𝑟
= 0.19.
this interaction was 𝑠𝑠𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖

The one-way ANOVA comparing RRMS participants

with “high” versus RRMS participants with “low” levels of depression was significant
(F(1,13)=17.69, p=0.001).
An ANOVA was calculated for IPS and IPA indices with depression as a covariate. A

Type I computational method was used to learn more about variance predictable from depression
(order of model entry was depression then RRMS). For IPS, depression was a significant
predictor in the model (F (1, 27) = 7.86, p=0.01) and not RRMS (F (1, 27) = 0.91, p=0.35). A
similar pattern occurred for IPA (depression: F (1, 27) = 2.64, p=0.05; RRMS: F (1, 27) = 0.02,
p=0.88).
To summarize, the relationship between these age matched samples and MicroCog scores
were similar to the results of our main analysis (above) in that there was a significant difference
in performance between RRMS and control groups for three out of four Level 2 and 3 outcome
variables (when not controlling for depression). There were not significant between group
differences for IPA. For GCF and GCP, a regression analysis support the differences between
groups were best accounted for by an interaction term between RRMS and depression. Further
analysis showed RRMS participants with “high” levels of depression perform worse on GCF and
GCP than RRMS participants with “low” depression levels. For IPS and IPA, RRMS did not
predict performance after controlling for depression.
Discussion
The results of the present study confirmed many but not all of our original hypotheses
and align well with findings from past studies of cognitive functioning in RRMS.
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MicroCog as a Measure of Cognitive Function in RRMS
The MicroCog was considered a promising candidate for measuring cognition in RRMS
based on its psychometric properties, normative data, evidence for its ability to detect cognitive
impairment in other clinical groups, and ease of administration. Before this study, there was no
evidence for how well the instrument detected cognitive impairment in RRMS.
In our sample of RRMS participants, 30.7% met criteria for cognitive impairment on the
MicroCog. This number is comparable to previously reported prevalence rates of cognitive
impairment in MS (Fischer et al., 2014). There were significant group differences between
groups for two index scores (GCP and IPS). While differences were not significant for Level 1
scores, effect sizes for Memory and Reasoning, two cognitive domains commonly impaired in
MS (Amato et al., 2011), were large. PASAT and SDMT were correlated with the MicroCog
IPS supporting construct validity. Correlations with covariates were similar to those identified in
past research in RRMS (discussed below).
The post-hoc analyses provided an estimate of the MicroCog’s ability to accurately
identify cognitive impairment in RRMS. Results indicated the MicroCog has high specificity but
low sensitivity, with an AUC value of 75.6. A cut-score of 93 on the IPS resulted in an
improved balance between sensitivity and specificity (66.7 and 78.6, respectively). These results
suggest the MicroCog was a fair to good test in discriminating cognitive impairment in this
sample and that its criterion validity is similar to other screening instruments for cognitive
impairment in MS (Parmenter, Weinstock-Guttman, Garg, Munschauer, & Benedict, 2007).
In order to learn how our findings matched past studies of cognitive impairment in
RRMS, effect sizes from our study were compared to those from the 2008 meta-analysis by
Praskash et al. Effect sizes for our study were calculated (SSbetween/SStotal) and then converted
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into Cohen’s d utilizing supplementary materials provided by Lakens (2013). Our results were
overall similar those in Praskash et al. (Table 12). The exception was Reasoning and Reaction
Time Level 1 index scores where we found a larger effect for reasoning and a smaller effect for
reaction time. This may have to do with differences in how the constructs were measured
between the two studies, or a characteristic of our sample.
Table 12
Comparison between effect sizes of current study and past meta-analysis

Cohen’s d

Hedge’s g; cognitive domain

(current study)

(Praskash et al., 2008)

IPS

0.97

0.65; information processing speed

Attention

0.34

0.54; attention*

Reasoning

0.70

0.31; concept formation and reasoning

Memory

0.82

0.61; memory

Spatial

0.44

0.53; construction

Reaction Time

0.14

0.56; vigilance/sustained attention

Note. *=Attention effect size from Prakash et al. 2008 was calculated by averaging effect sizes from the
following domains: vigilance/sustained attention, short term storage capacity, working memory,
selective/focused attention. GCP, GCF, and IPA were not compared because there were no comparable
constructs measured in Prakash et al. 2008.

Overall, these results support the MicroCog as a promising measure for cognitive
impairment in RRMS as they align well with past research. Further research into the
psychometrics of the MicroCog in RRMS (e.g., reliability, validity) is needed.
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Clinical Implications for Cognition in RRMS
Regarding those MicroCog index scores with significant group differences in control and
MS performance for ANOVAs (GCF, GCP, IPS, Memory, and Reasoning), when the covariate
depression was included in the analyses there were still significant group differences for GCP
and IPS. There were no longer significant group differences for GCF, Memory, or Reasoning
although effect sizes were large and low power and our conservative alpha likely contributed to
non-significant findings. The results of post-hoc analyses (where age was equivalent between
groups; age range was 30 to 53) indicated an interaction term between depression and group
membership (i.e., control or RRMS) accounted for a significant proportion of variance for GCF
and GCP. That is, higher depression scores were associated with worse cognitive scores for the
RRMS group than the control group. This was likely due to the fact that few individuals in the
control group reported symptoms of depression. Future studies would need to include a
depressed group of participants without RRMS in order to further verify an interaction exists.
The finding that RRMS participants with higher levels of depression performed worse than
RRMS participants with lower levels of depression supports that these conditions combined may
lead to worse performance on cognitive measures in RRMS. Of note, for IPS and IPA scores,
RRMS did not predict performance after controlling for depression.
There is evidence to support the possibility that depression in combination with RRMS
might put one at greater risk for performance difficulties on the MicroCog. First, the MicroCog
manual includes results for 19 participants with major depression diagnoses with an average
BDI-II score of 22.17 and no other mental health or medical conditions. The manual normative
data indicated the group mean performance was within the Average range for all index scores,
suggesting that depression alone does not typically influence MicroCog performance. Second,
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past reviews of depression in MS (discussed in “Introduction” section above) described MS
participants with severe depression had greater difficulties with working memory, executive
functioning, and information processing speed than participants with fewer depression
symptoms. Overlap between the physical symptoms of depression and MS have also been
studied (see below).
Regarding clinical covariates, the correlation between MSFC and MicroCog scores were
significant. Clinical status (MSFC score) should continue to be considered as a potential
correlate for MicroCog performance. This is an encouraging finding for the utility of the
MicroCog, given the MSFC is currently the gold standard for measuring clinical status in MS
(Ontaneda, LaRocca, Coetzee, & Rudick, 2012). Consistent with the findings in the post-hoc
analysis there was also a significant correlation identified between depression (BDI-II) and
MicroCog performance. Disease duration was not significantly related with MicroCog
performance but the scatterplots suggested a negative, linear relationship was present. This
variable should continue to be assessed with MicroCog performance, with a larger sample size.
There are inconsistent findings in the literature regarding correlation between disease duration
and cognitive impairment (Prakash et al. 2008, Rao et al., 1991c, Amato et al., 2001) suggesting
the influence of this variable is not fully understood. Prakash et al., 2008 identified in their
meta-analysis that disease course may be domain specific and more likely impacting measures of
learning and memory. We may have not detected a relationship because our analyses included
global summary scores of cognitive functioning or due to our small sample size resulting in
lower power. It may also be that disease duration correlates differently with cognitive
impairment depending on the period of disease duration (e.g., first five years, first 10 years, 10 to
20 years). Data suggests that cognitive deterioration may be most prominent in the first five
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years after disease onset (Reuter et al., 2010). In our sample, seven out of the 26 RRMS
participants had disease durations of seven years or less, and 19 participants’ disease duration
was 12 years or longer. Sex was not significantly correlated with MicroCog performance.
Of note, this study did not differentiate between somatic and non-somatic symptoms of
depression in RRMS and control subjects. This has become a more widely used strategy in MS
research, given the high overlap of somatic symptoms between MS and depression (Feinstein et
al., 2014). In fact, scores for the non-somatic symptoms of depression have been found to be a
stronger predictor of cognitive impairment than the somatic symptoms or when these symptoms
are combined (Sundgren, Maurex, Wahlin, Piehl, & Brisman, 2013). Future studies might help
differentiate between these symptom types and their relationships with MicroCog performance.
The a MicroCog was straightforward test to administer and almost all participants
reported no difficulties understanding the instructions provided. There were times that
participants had questions or comments for the examiner. These issues were resolved after a
short explanation was provided by the examiner. In a clinical setting it may be helpful for
examiner to be in the room to take notes on any behavioral observations (e.g., if a participant
says a certain cognitive task has been difficult for them their whole life, and not solely since their
RRMS diagnosis).
Conclusion
In conclusion, this study served as an important step in learning how the MicroCog
computerized battery of neuropsychological function might be utilized in clinical care with
RRMS patients and how it compares to past research of cognition in RRMS. The study supports
the MicroCog as a promising tool for use with RRMS patients.
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Overall the results of the current study aligned well with prior studies of cognition in
RRMS, including that RRMS participants performed worse than controls on cognitive tests and
high levels of depression likely influenced performance. Future studies can help confirm and
clarify these findings by including a larger sample size and comparison groups with a wider
range of depression and disability symptoms. This would help confirm how factors (e.g.,
RRMS, depression) account for a significant portion of cognitive difficulties as our small sample
may have influenced our ability to identify significant relationships and the analyses. Further
studies can also continue to establish psychometric properties of the MicroCog in RRMS
including reliability, validity, and sensitivity/specificity.
Strengths of the MicroCog are its straightforward administration, extensive normative
data, and the wealth of information available to the clinician about a patient’s performance. It
also has a specific measure of how processing speed influences performance within each subtest.
This is helpful in a patient population like RRMS, where performance deficits can vary so widely
between patients and processing speed is a dominant deficit.
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